AIMS/HYPOTHESIS: To determine the associations of baseline depression symptoms and use of antidepressant medicines (ADMs) with baseline cardiovascular disease (CVD) risk factors in Look AHEAD (Action for Health in Diabetes) trial participants. METHODS: Look AHEAD participants (n = 5,145; age 58.7 +/- 6.8 years; BMI 35.8 +/- 5.8 kg/m(2)) were assessed for CVD risk factors (elevated HbA(1c) or insulin use, elevated BP or antihypertensive use, elevated lipid levels or lipid-lowering medication, current smoking, BMI > or = 30 kg/m(2), lower peak exercise capacity assessed as metabolic equivalents [METs], and ankle-brachial index <0.9 or >1.3). Participants also completed the Beck Depression Inventory (BDI) and reported their use of ADMs. RESULTS: Of the participants, 14.7% had BDI scores > or = 11, consistent with mild-moderate depression, and 16.5% took ADMs; 4.4% had both depression markers (i.e. elevated symptom scores and took ADMs). In logistic regression analyses of CVD risk (elevated risk factor or use of medication to control the risk factor), controlled for demographic factors, continuous BDI scores and ADM use were each independently associated with elevated BP (or medication), current smoking, BMI > or = 30 kg/m(2) and lower MET values. ADM use was also associated with elevated serum lipids or use of lipid-lowering medication. CONCLUSIONS/ INTERPRETATION: Among Look AHEAD participants, depression symptoms or ADM use on entry to the study were each independently associated with a wide range of CVD risk factors. Future research should assess the temporal dynamics of the relationships of depression symptoms and ADM use with CVD risk factors. TRIAL REGISTRATION: Clinicaltrials.gov NCT00017953 FUNDING: This study is funded by the National Institutes of Health with additional support from the Centers for Disease Control and Prevention.
RCT Entities:
AIMS/HYPOTHESIS: To determine the associations of baseline depression symptoms and use of antidepressant medicines (ADMs) with baseline cardiovascular disease (CVD) risk factors in Look AHEAD (Action for Health in Diabetes) trial participants. METHODS: Look AHEAD participants (n = 5,145; age 58.7 +/- 6.8 years; BMI 35.8 +/- 5.8 kg/m(2)) were assessed for CVD risk factors (elevated HbA(1c) or insulin use, elevated BP or antihypertensive use, elevated lipid levels or lipid-lowering medication, current smoking, BMI > or = 30 kg/m(2), lower peak exercise capacity assessed as metabolic equivalents [METs], and ankle-brachial index <0.9 or >1.3). Participants also completed the Beck Depression Inventory (BDI) and reported their use of ADMs. RESULTS: Of the participants, 14.7% had BDI scores > or = 11, consistent with mild-moderate depression, and 16.5% took ADMs; 4.4% had both depression markers (i.e. elevated symptom scores and took ADMs). In logistic regression analyses of CVD risk (elevated risk factor or use of medication to control the risk factor), controlled for demographic factors, continuous BDI scores and ADM use were each independently associated with elevated BP (or medication), current smoking, BMI > or = 30 kg/m(2) and lower MET values. ADM use was also associated with elevated serum lipids or use of lipid-lowering medication. CONCLUSIONS/ INTERPRETATION: Among Look AHEAD participants, depression symptoms or ADM use on entry to the study were each independently associated with a wide range of CVD risk factors. Future research should assess the temporal dynamics of the relationships of depression symptoms and ADM use with CVD risk factors. TRIAL REGISTRATION: Clinicaltrials.gov NCT00017953 FUNDING: This study is funded by the National Institutes of Health with additional support from the Centers for Disease Control and Prevention.
Authors: Joost P van Melle; Peter de Jonge; Titia A Spijkerman; Jan G P Tijssen; Johan Ormel; Dirk J van Veldhuisen; Rob H S van den Brink; Maarten P van den Berg Journal: Psychosom Med Date: 2004 Nov-Dec Impact factor: 4.312
Authors: Stefan Lange; Hans Joachim Trampisch; Roman Haberl; Harald Darius; David Pittrow; Alexander Schuster; Berndt von Stritzky; Gerhart Tepohl; Jens Rainer Allenberg; Curt Diehm Journal: Atherosclerosis Date: 2005-02 Impact factor: 5.162
Authors: Donna H Ryan; Mark A Espeland; Gary D Foster; Steven M Haffner; Van S Hubbard; Karen C Johnson; Steven E Kahn; William C Knowler; Susan Z Yanovski Journal: Control Clin Trials Date: 2003-10
Authors: Heather S Lett; James A Blumenthal; Michael A Babyak; Andrew Sherwood; Timothy Strauman; Clive Robins; Mark F Newman Journal: Psychosom Med Date: 2004 May-Jun Impact factor: 4.312
Authors: Brett D Thombs; Peter de Jonge; James C Coyne; Mary A Whooley; Nancy Frasure-Smith; Alex J Mitchell; Marij Zuidersma; Chete Eze-Nliam; Bruno B Lima; Cheri G Smith; Karl Soderlund; Roy C Ziegelstein Journal: JAMA Date: 2008-11-12 Impact factor: 56.272
Authors: Ikuyo Imayama; Catherine M Alfano; Caitlin Mason; Chiachi Wang; Catherine Duggan; Kristin L Campbell; Angela Kong; Karen E Foster-Schubert; George L Blackburn; Ching-Yun Wang; Anne McTiernan Journal: Prev Med Date: 2013-07-13 Impact factor: 4.018
Authors: Helen P Hazuda; Sarah A Gaussoin; Rena R Wing; Susan Z Yanovski; Karen C Johnson; Mace Coday; Thomas A Wadden; Edward S Horton; Brent Van Dorsten; William C Knowler Journal: Diabetes Care Date: 2019-03-04 Impact factor: 19.112
Authors: Álvaro Camacho; Robyn L McClelland; Joseph A Delaney; Matthew A Allison; Bruce M Psaty; Dena E Rifkin; Stephen R Rapp; Moyses Szklo; Murray B Stein; Michael H Criqui Journal: J Clin Psychopharmacol Date: 2016-08 Impact factor: 3.153
Authors: Lindsay B Kimbro; Carol M Mangione; W Neil Steers; O Kenrik Duru; Laura McEwen; Andrew Karter; Susan L Ettner Journal: J Am Geriatr Soc Date: 2014-05-13 Impact factor: 5.562